List of Excipients in Branded Drug RINGERS IRRIGATION

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ICU Medical Inc	RINGERS IRRIGATION	sodium chloride, potassium chloride, and calcium chloride irrigant	0990-6140	WATER

Ringer's Irrigation Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Ringer's Irrigation is a sterile, preservative-free electrolyte solution used for irrigation during surgical and medical procedures. Its commercial value is driven less by molecular exclusivity than by manufacturing reliability, container performance, hospital contracting, and supply continuity. The strongest product strategy is a low-risk formulation with validated sterilization, broad container sizes, and differentiated packaging rather than added excipients.

What is Ringer's Irrigation?

Ringer's Irrigation is an aqueous sterile solution containing sodium chloride, potassium chloride, calcium chloride, and water for injection. It is intended for irrigation and is not labeled for intravenous administration.

A representative composition per liter is:

Component	Approximate concentration
Sodium chloride	8.6 g/L
Potassium chloride	0.3 g/L
Calcium chloride dihydrate	0.33 g/L
Water for injection	q.s. to 1 L
Preservative	None

The solution has an electrolyte profile designed to approximate extracellular fluid. Product labeling generally identifies an osmolarity near 309 mOsm/L and an acidic-to-near-neutral pH range, depending on the manufacturer and lot specification. Exact specifications must be controlled under the applicable product label and United States Pharmacopeia requirements.[1]

Ringer's Irrigation is used in surgical irrigation, wound irrigation, urologic procedures, arthroscopy, and other settings in which a sterile electrolyte solution is required.

What excipients are used in Ringer's Irrigation?

Ringer's Irrigation usually has no conventional functional excipients such as preservatives, surfactants, antioxidants, buffers, or viscosity modifiers. Water for injection is the principal vehicle.

The formulation has three practical categories of ingredients:

1. Sodium chloride, which provides sodium and chloride ions.
2. Potassium chloride, which provides potassium ions.
3. Calcium chloride, which provides calcium ions.
4. Water for injection, which is the sterile vehicle.

The absence of added excipients is commercially important. Preservatives can create tissue-irritation concerns, buffers can alter compatibility, and chelating agents can change calcium availability. A simple formulation reduces toxicological, compatibility, and regulatory complexity.

Why a no-additive formulation is commercially attractive

A preservative-free electrolyte solution offers several advantages:

• Lower risk of local irritation during tissue contact.
• Fewer extractables and leachables concerns from formulation additives.
• Easier compatibility assessment with surgical instruments and tissues.
• Lower formulation-development cost.
• Lower risk that an added excipient changes pH, osmolality, or ionic balance.
• Strong alignment with hospital preference for simple, ready-to-use sterile fluids.

The commercial tradeoff is that the manufacturer cannot create a strong formulation moat through proprietary excipients. Differentiation must come from container technology, presentation, quality systems, supply reliability, and service.

What formulation strategy is appropriate for Ringer's Irrigation?

The preferred formulation strategy is to preserve the established electrolyte composition and compete through process control and packaging.

Core formulation targets

A development program should control:

Quality attribute	Commercial relevance
Electrolyte concentration	Maintains clinical and compendial consistency
pH	Limits tissue irritation and container interaction
Osmolality	Supports physiological compatibility
Sterility	Required for surgical use
Bacterial endotoxins	Important for intraoperative exposure
Particulate matter	Critical for direct tissue and cavity irrigation
Visible clarity	Supports operating-room acceptance
Container integrity	Protects sterility through shelf life
Extractables and leachables	Controls packaging-related risk
Fill volume	Affects procedural usability and waste

The product should remain free of antimicrobial preservatives unless a specific regulatory and clinical rationale supports their use. Preservatives would add development burden and could reduce acceptance in sensitive surgical applications.

Should a buffer be added?

A buffer is generally unattractive. Ringer's Irrigation already has an established pH range, and unnecessary buffering can create compatibility problems with calcium salts, packaging materials, or concurrently used surgical products.

A buffered derivative could be commercially relevant only for a defined application, such as ophthalmic, urologic, or tissue-engineering use. That product would require a separate compatibility and clinical-use assessment rather than a simple reformulation of standard Ringer's Irrigation.

Should the product include antimicrobials?

Routine antimicrobial addition is commercially and technically weak. The product is supplied as a sterile, single-use or controlled-use solution. Antimicrobials may cause tissue toxicity, raise preservative-labeling issues, and create new extractables and compatibility questions.

The stronger strategy is terminal sterilization where compatible with the container and formulation, supported by validated aseptic processing controls when required by the product configuration.

What packaging opportunities exist for Ringer's Irrigation?

Packaging is the most credible source of product differentiation.

Flexible containers

Flexible bags are widely suited to irrigation because they are lightweight, stackable, and easy to use in operating rooms. Opportunities include:

• Improved tear resistance.
• Lower residual volume.
• Easier spike access.
• Reduced overwrap waste.
• Clearer labeling.
• Improved port design.
• Better handling with surgical irrigation pumps.
• Lower plastic content or recyclable materials where permitted.

The principal development risks are container-closure integrity, moisture loss, oxygen transmission, particulate generation, and extractables.

Rigid bottles

Rigid plastic bottles can support easy visual inspection and controlled pouring. They may appeal to facilities that prefer bottle-based gravity irrigation or require a stable container during open procedures.

The disadvantages are greater shipping volume, higher storage burden, and potentially more operating-room waste.

Large-volume presentations

Common commercial presentations include approximately 1,000 mL, 2,000 mL, 3,000 mL, and 5,000 mL configurations, depending on the manufacturer and market. Larger formats are attractive for orthopedics, wound care, and high-volume procedures, but they increase handling and spillage risks.

A portfolio should normally include:

• A smaller container for low-volume procedures.
• A 2- or 3-liter format for general surgery.
• A 5-liter format for high-volume irrigation.
• A pump-compatible presentation for arthroscopy and other procedural systems.

Dual-port and procedure-ready systems

A dual-port container can support controlled dispensing, connection to tubing, or use with irrigation pumps. Commercial value increases when the package reduces setup time and avoids transfer to a separate basin.

Potential claims should focus on package function, such as improved dispensing, lower residual volume, or compatibility with specified irrigation equipment. Any claim must be supported by device and drug-container regulations applicable to the product.

What FDA regulatory status applies to Ringer's Irrigation?

Ringer's Irrigation is regulated as a sterile drug product for irrigation. Its labeling must clearly distinguish irrigation use from intravenous administration. FDA labeling for Ringer's Irrigation products commonly includes warnings against injection and requires appropriate control of sterility, particulate matter, and container integrity.[2]

The regulatory pathway depends on the proposed product and reference product. A manufacturer seeking to market a conventional equivalent must address:

• Active ingredient identity and strength.
• Sterility and endotoxin controls.
• Container-closure system.
• Manufacturing process.
• Stability and shelf life.
• Labeling for irrigation use.
• Product quality and facility compliance.

The product is not interchangeable with Lactated Ringer's Injection. Lactated Ringer's contains sodium lactate and is administered by intravenous infusion under a different labeling framework. A Ringer's Irrigation product should not make claims that imply intravenous use.

What is the Orange Book status of Ringer's Irrigation?

Ringer's Irrigation generally does not have the type of branded small-molecule Orange Book patent structure associated with high-value prescription products. The commercial market is primarily a multisource sterile-fluid market.

The Orange Book is relevant where a product has an approved application with listed patents and exclusivity. For a conventional electrolyte irrigation product, the key commercial barriers are more likely to be:

• FDA-approved or lawfully marketed product status.
• Sterile manufacturing capacity.
• Facility inspection history.
• Container qualification.
• Hospital purchasing contracts.
• Supply-chain reliability.
• Product-specific quality documentation.

A product-specific patent search should examine formulation, packaging, manufacturing, and irrigation-system claims. Standard Ringer's composition is old and difficult to protect broadly with a composition-of-matter patent.

When does Ringer's Irrigation lose exclusivity?

Ringer's Irrigation generally does not have a predictable single patent-expiration date comparable to a newly approved branded drug. The basic electrolyte formulation is established, and market entry is usually governed by regulatory approval, manufacturing readiness, and commercial contracting.

Patent and exclusivity assessment

Protection category	Likely commercial importance
Basic electrolyte composition	Low; composition is established
Preservative-free formulation	Low to moderate; difficult to protect broadly
pH or osmolality range	Low unless linked to a novel use or process
Sterilization process	Moderate if technically specific
Flexible bag or port design	Moderate to high
Pump-compatible presentation	Moderate
Extractables-control process	Moderate as know-how, weaker as broad patent matter
Procedure-specific method of use	Moderate, but enforcement may be difficult
Manufacturing know-how	High practical value
Supply contracts	High commercial value

A generic manufacturer would rarely need to design around a valuable core composition patent. The more relevant risk is whether a patent covers a proprietary container, delivery system, or manufacturing process.

Are there Paragraph IV challenges for Ringer's Irrigation?

Paragraph IV litigation is not usually the central market-access issue for standard Ringer's Irrigation. Paragraph IV certification applies to an abbreviated new drug application that seeks approval against a listed reference drug with relevant Orange Book patents.

For a conventional Ringer's Irrigation product, competitive entry is more likely to depend on the applicant's ability to establish the required quality, sterility, labeling, and manufacturing controls than on defeating a branded patent estate.

If a supplier develops a differentiated bag, closure, pump interface, or procedure-specific presentation, patent disputes could arise around those features. Such disputes would concern formulation or delivery-system claims rather than the basic Ringer's solution itself.

What formulation patents protect Ringer's Irrigation?

Broad patents covering sodium chloride, potassium chloride, calcium chloride, and water are unlikely to provide durable exclusivity because the composition is established and technically straightforward.

Potentially defensible patent subjects include:

• A defined electrolyte composition with a novel stability profile.
• A calcium-containing solution with reduced precipitation.
• A container system that minimizes ion interaction or leachables.
• A low-residual-volume irrigation bag.
• A specialized pump interface.
• A sterile manufacturing process that improves shelf life.
• A formulation optimized for a defined surgical application.
• A combination of solution and irrigation equipment.

The strongest patent strategy would connect the composition to a measurable technical result. A narrow claim to conventional ingredients without a demonstrated unexpected property would face substantial validity risk.

How strong is the Ringer's Irrigation patent estate?

The core patent estate is weak because the formulation is old, simple, and readily reproducible. The strongest protection is likely to exist outside the solution itself.

Relative patent strength

Asset	Patent strength	Commercial durability
Basic Ringer's composition	Low	Low
Preservative-free formulation	Low	Low
Novel container film	Moderate	Moderate
Specialized closure or port	Moderate	Moderate
Pump-integrated delivery system	Moderate to high	Moderate to high
Manufacturing process	Moderate	High if difficult to replicate
Hospital-specific packaging	Low to moderate	High through contracts rather than patents
Brand and supplier qualification	Not patent protection	High in practice

Trade secrets, process parameters, supplier qualification, and quality documentation may produce more durable commercial protection than patents.

What commercial opportunities exist for Ringer's Irrigation?

The most attractive opportunities are in supply reliability, procedure-specific packaging, and hospital workflow reduction.

Hospital and ambulatory surgery supply

Hospitals often value sterile-fluid suppliers that can provide dependable delivery across multiple sizes. A manufacturer can build a portfolio around:

• Operating-room irrigation.
• Orthopedic procedures.
• Arthroscopy.
• Urology.
• Wound care.
• Emergency and trauma settings.
• Ambulatory surgery centers.
• Veterinary surgery.

The product can be bundled with tubing, irrigation pumps, warming systems, and procedure kits, subject to applicable device and drug rules.

Premium packaging

A premium product could command a higher price if it provides measurable operational benefits, including:

• Faster setup.
• Lower spillage.
• Less waste.
• Better visibility.
• Improved pump compatibility.
• Reduced storage space.
• Easier disposal.
• Lower risk of accidental intravenous use through distinctive labeling and connector design.

The commercial proposition should quantify labor savings and waste reduction rather than rely on formulation novelty.

Regional manufacturing and shortage mitigation

Sterile fluids are vulnerable to plant shutdowns, transportation delays, component shortages, and capacity constraints. Regional fill-finish capacity can create a strong market position even without patent protection.

Potential advantages include:

• Shorter delivery routes.
• Dual sourcing of plastic resin and closure components.
• Multiple sterilization-capable sites.
• Inventory buffers for large-volume bags.
• Contract manufacturing for hospital systems.
• Private-label supply for distributors.

FDA shortage communications and enforcement priorities make manufacturing resilience commercially relevant for sterile products.[3]

Lower-waste product formats

Hospitals face pressure to reduce operating-room plastic waste. Opportunities include lower-material bags, optimized overwraps, recyclable secondary packaging, and container designs that reduce residual solution.

Environmental claims require substantiation. A lower-plastic format must still meet sterility, integrity, transportation, and shelf-life requirements.

How does Ringer's Irrigation compare with Lactated Ringer's Injection?

Ringer's Irrigation and Lactated Ringer's Injection are not interchangeable products.

Attribute	Ringer's Irrigation	Lactated Ringer's Injection
Primary use	Surgical or medical irrigation	Intravenous fluid administration
Administration route	Irrigation only	Intravenous administration
Lactate	Not present in conventional Ringer's Irrigation	Present as sodium lactate
Regulatory positioning	Sterile irrigation solution	Injectable large-volume parenteral
Clinical risk	Tissue and procedure compatibility	Systemic administration, electrolyte and fluid risks
Commercial competition	Sterile irrigation suppliers	Injectable fluid manufacturers
Packaging needs	Pouring, tubing, irrigation pump use	IV administration and infusion-set compatibility

Confusing the two products creates regulatory and clinical risk. A commercial product must use route-specific labeling, packaging, and connector controls.

What generic entry risks exist for Ringer's Irrigation?

Generic entry risk is high for the basic solution because the formulation is simple and the technology is mature. A new supplier can compete if it can meet regulatory and operational requirements.

The largest barriers are:

• Sterile manufacturing qualification.
• Container-closure validation.
• Reliable supply of medical-grade packaging.
• Low particulate levels.
• Stable calcium-containing formulation.
• Large-volume fill-finish capacity.
• Hospital vendor qualification.
• FDA inspection readiness.
• Distribution economics.

The market has low formulation barriers but meaningful execution barriers. A low-cost entrant without reliable supply may fail to displace an established supplier.

What licensing deals are relevant to Ringer's Irrigation?

Licensing is more likely to involve packaging, delivery systems, or manufacturing technology than the Ringer's composition.

Potential deal structures include:

• Licensing a low-residual-volume bag.
• Contract manufacturing for an established pharmaceutical distributor.
• Co-development with an irrigation-pump company.
• Private-label supply to hospital group purchasing organizations.
• Regional distribution rights.
• Technology transfer for sterile fill-finish.
• Licensing of recyclable or lower-extractables packaging.

An attractive licensing asset should solve a documented procurement or operating-room problem. A conventional Ringer's formulation alone is unlikely to support substantial royalty economics.

What geographic opportunities exist?

The product has broad geographic utility because sterile electrolyte irrigation is used across surgical markets. Geographic expansion depends on local registration, pharmacopeial standards, labeling, and packaging requirements.

Priority markets may include:

• United States and Canada.
• European Union and United Kingdom.
• Japan and Australia.
• Gulf states.
• Latin America.
• Southeast Asia.

The primary localization issues are container size, language, route-of-administration warnings, pharmacopeial conformity, and local sterile-manufacturing requirements. Regional packaging can reduce freight costs because large-volume sterile fluids are expensive to ship relative to their ingredient value.

Key Takeaways

• Ringer's Irrigation is a simple sterile electrolyte solution with sodium chloride, potassium chloride, calcium chloride, and water for injection.
• Conventional excipient innovation has limited value. A preservative-free, additive-free formulation is usually the strongest baseline.
• Packaging, container integrity, pump compatibility, low residual volume, and reduced waste provide the clearest commercial differentiation.
• The basic formulation has weak patent exclusivity potential.
• Manufacturing capacity, quality systems, hospital contracts, and supply reliability are more important than core composition patents.
• Paragraph IV litigation and Orange Book patent barriers are generally less important than sterile manufacturing and regulatory execution.
• The strongest licensing opportunities involve packaging, delivery systems, and contract manufacturing.
• Ringer's Irrigation must remain clearly differentiated from Lactated Ringer's Injection, which is an intravenous product.
• Generic-entry risk is high for the basic product, but operational barriers can protect incumbent suppliers in practice.

FAQs

Is Ringer's Irrigation the same as normal saline irrigation?

No. Normal saline irrigation contains sodium chloride in water, while Ringer's Irrigation also contains potassium and calcium salts.

Can Ringer's Irrigation be administered intravenously?

No. Ringer's Irrigation is labeled for irrigation and should not be substituted for an intravenous Ringer's or Lactated Ringer's product.

Does Ringer's Irrigation contain preservatives?

Conventional products are preservative-free. The applicable manufacturer label controls the exact formulation and storage instructions.

Can a manufacturer patent a new Ringer's Irrigation bag?

Yes. A bag, port, closure, film, pump interface, or manufacturing process may be patentable if it is novel, non-obvious, and adequately supported. The basic electrolyte solution is unlikely to provide broad new-patent protection.

What is the most valuable commercial improvement for Ringer's Irrigation?

A validated package that reduces setup time, waste, residual volume, or compatibility problems is likely to have greater commercial value than adding a new excipient.

References

1. United States Pharmacopeia. (2024). Ringer's irrigation, USP. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

2. U.S. Food and Drug Administration. (n.d.). DailyMed: Ringer's irrigation product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2019). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics-chemistry-manufacturing-and-controls-documentation